Is hormone therapy used for MDS and how does it work

Hormone Therapy and MDS: What the Evidence Shows

Great question. Based on current medical guidelines, hormone therapy is NOT a standard treatment for MDS (myelodysplastic syndromes). Let me explain why and what treatments are actually used instead.

Why Hormone Therapy Doesn't Apply to MDS

MDS is fundamentally different from cancers like breast cancer that respond to hormone therapy. Here's the key distinction:

Hormone-responsive cancers (like some breast cancers) have cancer cells that grow when exposed to hormones like estrogen. Blocking those hormones stops the cancer growth.

MDS, on the other hand, is a disorder of blood-forming cells in the bone marrow. The problem isn't that these cells respond to hormones—it's that they:

• Don't develop properly into healthy blood cells
• Have genetic mutations (changes in their DNA)
• Produce too few or abnormal blood cells
• May progress toward acute myeloid leukemia (AML)

What Treatments ARE Used for MDS Instead

According to the NCCN Guidelines for Myelodysplastic Syndromes (Version 1.2026), the main treatment approaches include:

For Lower-Risk MDS:

• Supportive care (blood transfusions, growth factors)
• Lenalidomide (for patients with deletion 5q, a specific chromosomal abnormality)
• Erythropoiesis-stimulating agents (ESAs) like epoetin alfa—these boost red blood cell production
• Imetelstat or Luspatercept (newer agents that help with anemia)
• Immunosuppressive therapy for select patients

For Higher-Risk MDS:

• Hypomethylating agents (HMAs) like azacitidine or decitabine—these are DNA-modifying drugs
• Targeted therapies for specific mutations:
  • Ivosidenib (for IDH1 mutations)
  • Enasidenib (for IDH2 mutations)
• Stem cell transplantation (bone marrow transplant) for eligible patients

The Role of Genetic Mutations

According to NCCN Guidelines, doctors now test MDS patients for specific gene mutations because they directly influence treatment decisions. Mutations in genes like TP53, ASXL1, RUNX1, SF3B1, and splicing factor genes help determine prognosis and guide which therapy might work best.

Questions to Ask Your Doctor

If you have MDS, these questions can help you understand your specific treatment plan:

1. What is my IPSS-R risk score? (This is the standard prognostic scoring system that guides treatment)
2. What genetic mutations were found in my bone marrow? (This directly affects which treatments are recommended)
3. Am I a candidate for any of the newer targeted therapies like imetelstat or luspatercept?
4. What is the goal of my treatment? (Managing symptoms, slowing progression, or preparing for transplant?)
5. How will we monitor my response to treatment? (Blood counts, bone marrow biopsies, genetic testing)

Bottom Line

MDS treatment is highly personalized based on your risk level and specific genetic mutations—not on hormone sensitivity. Your oncologist will determine the most appropriate approach for YOUR case based on your complete clinical picture, including your age, overall health, and specific MDS characteristics.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Myelodysplastic Syndromes, Version 1.2026